Leile Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leile Tang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Xun Liu
Department of Nephrology Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou Guangdong China
3 shared publications - Xinghua Guo
Department of Rheumatology Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou Guangdong China
2 shared publications Ying Deng
Department of Nephrology Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou Guangdong China
2 shared publicationsCaiLian Cheng
Department of Nephrology, Third Affiliated Hospital of Sun Yat-Sen University
1 shared publicationHuaLiang Liang
Department of Nephrology, Third Affiliated Hospital of Sun Yat-Sen University
1 shared publicationHualiang Liang
Department of Nephrology Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou Guangdong China
1 shared publication
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 88 (3) , 237-247
Asiatic Acid Mitigates PM2.5-Elicited Cardiomyocyte Pyroptosis via Suppression of mtDNA-Driven cGAS-STING-NLRP3 Signaling
Fine particulate matter (PM2.5) is a pervasive air pollutant strongly linked to cardiovascular morbidity, yet effective countermeasures remain elusive. Here, we report that the natural triterpenoid asiatic acid (AA) protects against PM2.5-induced cardiotoxicity in male BALB/c mice by interrupting a mitochondrial DNA (mtDNA)-driven pyroptotic cascade. Animals exposed to intranasal PM2.5 (16.2 mg·kg⁻¹, every 48 hours for 21 days) developed cardiac hypertrophy, contractile dysfunction, extensive fibrosis and ultrastructural mitochondrial damage concomitant with cytosolic release of mtDNA fragments (cytochrome c oxidase subunit I [CO1], NADH dehydrogenase subunit 1 [ND1], cytochrome b [Cytb]), down-regulation of mitochondrial transcription factor A (TFAM), and robust activation of cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signalling (cGAS, STING, phosphorylated TANK-binding kinase 1 [p-TBK1], phosphorylated interferon regulatory factor 3 [p-IRF3]). Downstream, NOD-like receptor protein 3 (NLRP3) inflammasome assembly, caspase-1 cleavage, gasdermin D pore formation and maturation of interleukin-1 beta (IL-1β)/interleukin-18 (IL-18) were markedly elevated. Oral administration of AA (12.5 or 25 mg·kg⁻¹ from day 7) dose-dependently restored TFAM expression, reduced cytosolic mtDNA, blunted cGAS-STING-NLRP3 axis activation, attenuated pyroptosis and preserved cardiac architecture and function. These findings identify mtDNA-triggered cGAS-STING-NLRP3 signalling as a critical pathway underlying PM2.5-elicited cardiomyocyte pyroptosis and establish AA as a promising therapeutic agent against air-pollution-associated cardiovascular injury.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 88 (3) , 237-247
Asiatic Acid Mitigates PM2.5-Elicited Cardiomyocyte Pyroptosis via Suppression of mtDNA-Driven cGAS-STING-NLRP3 Signaling
Fine particulate matter (PM2.5) is a pervasive air pollutant strongly linked to cardiovascular morbidity, yet effective countermeasures remain elusive. Here, we report that the natural triterpenoid asiatic acid (AA) protects against PM2.5-induced cardiotoxicity in male BALB/c mice by interrupting a mitochondrial DNA (mtDNA)-driven pyroptotic cascade. Animals exposed to intranasal PM2.5 (16.2 mg·kg⁻¹, every 48 hours for 21 days) developed cardiac hypertrophy, contractile dysfunction, extensive fibrosis and ultrastructural mitochondrial damage concomitant with cytosolic release of mtDNA fragments (cytochrome c oxidase subunit I [CO1], NADH dehydrogenase subunit 1 [ND1], cytochrome b [Cytb]), down-regulation of mitochondrial transcription factor A (TFAM), and robust activation of cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signalling (cGAS, STING, phosphorylated TANK-binding kinase 1 [p-TBK1], phosphorylated interferon regulatory factor 3 [p-IRF3]). Downstream, NOD-like receptor protein 3 (NLRP3) inflammasome assembly, caspase-1 cleavage, gasdermin D pore formation and maturation of interleukin-1 beta (IL-1β)/interleukin-18 (IL-18) were markedly elevated. Oral administration of AA (12.5 or 25 mg·kg⁻¹ from day 7) dose-dependently restored TFAM expression, reduced cytosolic mtDNA, blunted cGAS-STING-NLRP3 axis activation, attenuated pyroptosis and preserved cardiac architecture and function. These findings identify mtDNA-triggered cGAS-STING-NLRP3 signalling as a critical pathway underlying PM2.5-elicited cardiomyocyte pyroptosis and establish AA as a promising therapeutic agent against air-pollution-associated cardiovascular injury.
- 15 July 2026
- Published by Wiley in Nephrology
- Vol. 31 (7) , e70232
Comparison of Electronic Health Data‐Based Frailty Assessment Tools for Prediction of Adverse Outcomes of Patients With Chronic Kidney Disease
Aim: To compare four electronic health record (EHR)‐based frailty tools—the Hospital Frailty Risk Score (HFRS), Johns Hopkins Adjusted Clinical Groups Frailty Indicator (CFI), Electronic Frailty Index (eFI) and a Laboratory‐based Frailty Index (FI‐Lab)—in predicting progression and all‐cause mortality in hospitalised patients with chronic kidney disease (CKD). Methods: This retrospective study evaluated the indices in two cohorts: a single‐centre cohort ( n = 5715) for CKD progression and the Medical Information Mart for Intensive Care (MIMIC) database ( n = 2674) for mortality. We used Cox proportional hazards regression for association analyses. The incremental predictive value of adding frailty indices to established risk models was quantified using the area under the curve (AUC), net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: Correlations between the frailty indices were weak to moderate (Spearman's ρ = 0.205–0.451). In adjusted analyses, CFI, eFI and FI‐Lab were associated with a higher risk of CKD progression, whereas HFRS was not. In the MIMIC cohort, all four indices were significantly associated with all‐cause mortality. Notably, the CFI association was non‐significant in patients < 65 years for both CKD progression and 28‐day mortality. For predictive enhancement, adding FI‐Lab and eFI to established CKD risk models significantly improved progression prediction (ΔAUC p < 0.05), yielding substantial reclassification (NRI: 0.376–0.498) and discrimination (IDI: 0.032–0.048). For mortality prediction, all indices improved baseline severity scores, with FI‐Lab providing the greatest incremental value. Conclusion: Among the evaluated EHR‐based frailty indices, FI‐Lab offers the most robust utility for risk stratification in hospitalised patients with CKD, followed closely by eFI.
- 15 July 2026
- Published by Wiley in Nephrology
- Vol. 31 (7) , e70232
Comparison of Electronic Health Data‐Based Frailty Assessment Tools for Prediction of Adverse Outcomes of Patients With Chronic Kidney Disease
Aim: To compare four electronic health record (EHR)‐based frailty tools—the Hospital Frailty Risk Score (HFRS), Johns Hopkins Adjusted Clinical Groups Frailty Indicator (CFI), Electronic Frailty Index (eFI) and a Laboratory‐based Frailty Index (FI‐Lab)—in predicting progression and all‐cause mortality in hospitalised patients with chronic kidney disease (CKD). Methods: This retrospective study evaluated the indices in two cohorts: a single‐centre cohort ( n = 5715) for CKD progression and the Medical Information Mart for Intensive Care (MIMIC) database ( n = 2674) for mortality. We used Cox proportional hazards regression for association analyses. The incremental predictive value of adding frailty indices to established risk models was quantified using the area under the curve (AUC), net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: Correlations between the frailty indices were weak to moderate (Spearman's ρ = 0.205–0.451). In adjusted analyses, CFI, eFI and FI‐Lab were associated with a higher risk of CKD progression, whereas HFRS was not. In the MIMIC cohort, all four indices were significantly associated with all‐cause mortality. Notably, the CFI association was non‐significant in patients < 65 years for both CKD progression and 28‐day mortality. For predictive enhancement, adding FI‐Lab and eFI to established CKD risk models significantly improved progression prediction (ΔAUC p < 0.05), yielding substantial reclassification (NRI: 0.376–0.498) and discrimination (IDI: 0.032–0.048). For mortality prediction, all indices improved baseline severity scores, with FI‐Lab providing the greatest incremental value. Conclusion: Among the evaluated EHR‐based frailty indices, FI‐Lab offers the most robust utility for risk stratification in hospitalised patients with CKD, followed closely by eFI.
- Open Access
- 2 November 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2577839
Baseline and long-term frailty transitions and rapid estimated glomerular filtration rate decline: evidence from two large population-based studies
Frailty is widely recognized to be associated with kidney function decline, but its longitudinal relationship with rapid estimated glomerular filtration rate (eGFR) decline remains unclear. This study examined associations between frailty measures and rapid eGFR decline using both frailty phenotype (FP) and frailty index (FI) in two large cohorts. We analyzed baseline frailty data from the China Health and Retirement Longitudinal Study (CHARLS) and Health and Retirement Study (HRS), with longitudinal trajectory analysis in HRS participants. Rapid eGFR decline was defined as annual decrease ≥4 mL/min/1.73 m2/year. Multiple imputation with inverse probability weighting addressed missing data and selection bias. Using FP criteria, frailty was significantly associated with higher odds of rapid eGFR decline compared to non-frail individuals (CHARLS: OR 1.93, 95% CI 1.13-3.29; HRS: OR 1.48, 95% CI 1.10-1.99). Longitudinally, progression from non-frail to pre-frail/frail status was associated with 27% higher odds, while improvement from pre-frail status was associated with 35% lower odds. Frailty improvement in baseline-frail individuals showed no significant effect. Each 1-point annual increase in FP score was associated with 91% higher odds (OR 1.91, 95% CI 1.46-2.51). FI assessment yielded consistent results with optimal population-specific thresholds (FI ≥ 0.25 for CHARLS, FI ≥ 0.32 for HRS). Reverse association analysis revealed bidirectional relationships, more pronounced among participants with baseline eGFR 2. Both baseline frailty and frailty progression are independently associated with rapid eGFR decline, supporting the potential value of frailty assessment in identifying patients at risk for kidney function decline.
- 2 November 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2577839
Open AccessBaseline and long-term frailty transitions and rapid estimated glomerular filtration rate decline: evidence from two large population-based studies
Frailty is widely recognized to be associated with kidney function decline, but its longitudinal relationship with rapid estimated glomerular filtration rate (eGFR) decline remains unclear. This study examined associations between frailty measures and rapid eGFR decline using both frailty phenotype (FP) and frailty index (FI) in two large cohorts. We analyzed baseline frailty data from the China Health and Retirement Longitudinal Study (CHARLS) and Health and Retirement Study (HRS), with longitudinal trajectory analysis in HRS participants. Rapid eGFR decline was defined as annual decrease ≥4 mL/min/1.73 m2/year. Multiple imputation with inverse probability weighting addressed missing data and selection bias. Using FP criteria, frailty was significantly associated with higher odds of rapid eGFR decline compared to non-frail individuals (CHARLS: OR 1.93, 95% CI 1.13-3.29; HRS: OR 1.48, 95% CI 1.10-1.99). Longitudinally, progression from non-frail to pre-frail/frail status was associated with 27% higher odds, while improvement from pre-frail status was associated with 35% lower odds. Frailty improvement in baseline-frail individuals showed no significant effect. Each 1-point annual increase in FP score was associated with 91% higher odds (OR 1.91, 95% CI 1.46-2.51). FI assessment yielded consistent results with optimal population-specific thresholds (FI ≥ 0.25 for CHARLS, FI ≥ 0.32 for HRS). Reverse association analysis revealed bidirectional relationships, more pronounced among participants with baseline eGFR 2. Both baseline frailty and frailty progression are independently associated with rapid eGFR decline, supporting the potential value of frailty assessment in identifying patients at risk for kidney function decline.
- Open Access
- 1 November 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 5273-5285
Predictive Effect of System Inflammation Response Index for Progression of Chronic Kidney Disease in Non-Dialyzing Patient
Purpose: Scant research has been conducted on the interplay between the systemic inflammation response index (SIRI) and chronic kidney disease (CKD). The present study endeavors to meticulously scrutinize the association between SIRI and renal function. Additionally, we aim to assess its efficacy in predicting the progression of CKD in non-dialysis patients. Patients and Methods: Adult patients with CKD who were not undergoing dialysis were enrolled, and follow-up data were obtained. Data from distinct groups were extracted and meticulously compared. A comprehensive analytical approach was adopted, including logistic regression analysis, Kaplan-Meier analysis, Cox proportional hazards regression analysis, and subgroup analysis. Results: Our study included 1420 patients, with a mean age of 61 ± 17 years, and 63% were male. 244 (17.2%) patients experienced the progression of CKD. As the level of ln(SIRI) increased, patients tended to be older, with a higher proportion of males, and increased prevalence rates of hypertension, stroke, heart failure, and progression of CKD. Additionally, the levels of baseline creatinine and C-reactive protein were elevated, while the levels of estimated glomerular filtration rate and hemoglobin decreased. Upon adjusting for demographic and biochemical variables, logistic regression analysis indicated that ln(SIRI) was independently associated with advanced CKD in pre-dialysis patients (OR=1.59, 95% CI: 1.29– 1.95, P< 0.001). Moreover, Cox proportional-hazard analysis revealed that ln(SIRI) independently predicted CKD progression (HR: 1.3, 95% CI: 1.07– 1.59, P=0.009). Conducting a subgroup analysis, we observed significant interactions between ln(SIRI) levels and gender (p< 0.001), age (p=0.046), and hypertension (p=0.028) in relation to the progression of CKD. Conclusion: Our study’s findings demonstrate a significant association between SIRI and fundamental renal function, and independently establish a correlation between SIRI and the progression of CKD in pre-dialysis patients. These observations suggest that SIRI holds promise as a potential predictor for CKD progression.
- 1 November 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 5273-5285
Open AccessPredictive Effect of System Inflammation Response Index for Progression of Chronic Kidney Disease in Non-Dialyzing Patient
Purpose: Scant research has been conducted on the interplay between the systemic inflammation response index (SIRI) and chronic kidney disease (CKD). The present study endeavors to meticulously scrutinize the association between SIRI and renal function. Additionally, we aim to assess its efficacy in predicting the progression of CKD in non-dialysis patients. Patients and Methods: Adult patients with CKD who were not undergoing dialysis were enrolled, and follow-up data were obtained. Data from distinct groups were extracted and meticulously compared. A comprehensive analytical approach was adopted, including logistic regression analysis, Kaplan-Meier analysis, Cox proportional hazards regression analysis, and subgroup analysis. Results: Our study included 1420 patients, with a mean age of 61 ± 17 years, and 63% were male. 244 (17.2%) patients experienced the progression of CKD. As the level of ln(SIRI) increased, patients tended to be older, with a higher proportion of males, and increased prevalence rates of hypertension, stroke, heart failure, and progression of CKD. Additionally, the levels of baseline creatinine and C-reactive protein were elevated, while the levels of estimated glomerular filtration rate and hemoglobin decreased. Upon adjusting for demographic and biochemical variables, logistic regression analysis indicated that ln(SIRI) was independently associated with advanced CKD in pre-dialysis patients (OR=1.59, 95% CI: 1.29– 1.95, P< 0.001). Moreover, Cox proportional-hazard analysis revealed that ln(SIRI) independently predicted CKD progression (HR: 1.3, 95% CI: 1.07– 1.59, P=0.009). Conducting a subgroup analysis, we observed significant interactions between ln(SIRI) levels and gender (p< 0.001), age (p=0.046), and hypertension (p=0.028) in relation to the progression of CKD. Conclusion: Our study’s findings demonstrate a significant association between SIRI and fundamental renal function, and independently establish a correlation between SIRI and the progression of CKD in pre-dialysis patients. These observations suggest that SIRI holds promise as a potential predictor for CKD progression.